Nidogen-1 is a novel extracellular ligand for the NKp44 activating receptor

Gaggero, Silvia; Bruschi, Maurizio; Petretto, Andrea; Parodi, Monica; Zotto, Genny Del; Lavarello, Chiara; Prato, Carola; Santucci, Laura; Barbuto, Alessandra; Bottino, Cristina; Candiano, Giovanni; Moretta, Alessandro; Vitale, Massimo; Moretta, Lorenzo; Cantoni, Claudia

doi:10.1080/2162402x.2018.1470730

Cited by 59 publications

(51 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ii) Tumor cells may also express decoy ligands, capable of inhibiting the signaling of NK cell activating receptors, or even inducing their internalization from the NK cell surface. The soluble form of the extracellular matrix (ECM)-associated nidogen-1 glycoprotein (sNID1) and the β-galactoside binding protein galectin-3 have recently been described as decoy ligands for NKp44 and NKp30, respectively [180,181]. Ligand shedding from the tumor cell surface represents another source of decoy ligands.…”

Section: Immunosuppressionmentioning

confidence: 99%

Mechanisms of Resistance to NK Cell Immunotherapy

Sordo‐Bahamonde

Vitale

Lorenzo‐Herrero

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Immunotherapy has recently been a major breakthrough in cancer treatment. Natural killer (NK) cells are suitable targets for immunotherapy owing to their potent cytotoxic activity that may target cancer cells in a major histocompatibility complex (MHC) and antigen-unrestricted manner. Current therapies targeting NK cells include monoclonal antibodies that promote NK cell antibody-dependent cell-mediated cytotoxicity (ADCC), hematopoietic stem cell transplantation (HSCT), the adoptive transfer of NK cells, the redirection of NK cells using chimeric antigen receptor (CAR)-NK cells and the use of cytokines and immunostimulatory drugs to boost the anti-tumor activity of NK cells. Despite some encouraging clinical results, patients receiving these therapies frequently develop resistance, and a myriad of mechanisms of resistance affecting both the immune system and cancer cells have been reported. A first contributing factor that modulates the efficacy of the NK cell therapy is the genetic profile of the individual, which regulates all aspects of NK cell biology. Additionally, the resistance of cancer cells to apoptosis and the immunoediting of cancer cells, a process that decreases their immunogenicity and promotes immunosuppression, are major determinants of the resistance to NK cell therapy. Consequently, the efficacy of NK cell anti-tumor therapy is specific to each patient and disease. The elucidation of such immunosubversive mechanisms is crucial to developing new procedures and therapeutic strategies to fully harness the anti-tumor potential of NK cells.

show abstract

Section: Immunosuppressionmentioning

confidence: 99%

Mechanisms of Resistance to NK Cell Immunotherapy

Sordo‐Bahamonde

Vitale

Lorenzo‐Herrero

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…It should also be mentioned that soluble NCR ligands have recently been discovered. They include the complement factor P for NKp46, the platelet‐derived growth factor P and Nidogen‐1 for NKp44 . Moreover, NKG2D specifically binds to MICA/B and ULBPs, and DNAM‐1 is specific for poliovirus receptor and nectin‐2, both components of the cellular junctions .…”

Section: Regulation Of Nk Cell Function: Role Of Inhibitory and Activmentioning

confidence: 99%

“…They include the complement factor P for NKp46, the platelet-derived growth factor P and Nidogen-1 for NKp44. [88][89][90] Moreover, NKG2D specifically binds to MICA/B and ULBPs, and DNAM-1 is specific for poliovirus receptor and nectin-2, both components of the cellular junctions. [91][92][93] The function of these main activating receptors can be amplified by the signaling lymphocyte activation molecule family receptors, whose expression is confined to hematological cells.…”

Section: Non Hla-specific Activating Receptorsmentioning

confidence: 99%

Natural killer cells: From surface receptors to the cure of high‐risk leukemia (Ceppellini Lecture)

Falco

Pende

Munari

et al. 2019

HLA

Self Cite

View full text Add to dashboard Cite

Natural killer (NK) cells are innate immune effector cells involved in the first line of defense against viral infections and malignancies. In the last three decades, the identification of HLA class I‐specific inhibitory killer immunoglobulin‐like receptors (KIR) and of the main activating receptors has strongly improved our understanding of the mechanisms regulating NK cell functions. The increased knowledge on how NK cells discriminate healthy cells from damaged cells has made it possible to transfer basic research notions to clinical applications. Of particular relevance is the strong NK‐mediated anti‐leukemia effect in haploidentical hematopoietic stem cell transplantation to cure high‐risk leukemia.

show abstract

“…NCR also interact with soluble ligands with either agonist or antagonist activity. For example, PDGF‐DD and Nidogen‐1 bind to NKp44 inducing NK cell activation and inhibition, respectively . Finally, a role for other activating receptors such as DNAM‐1 belonging to the nectin family and 2B4 belonging to the SLAM family have been also described …”

Section: Introductionmentioning

confidence: 99%

“…For example, PDGF-DD and Nidogen-1 bind to NKp44 inducing NK cell activation and inhibition, respectively. 17,18 Finally, a role for other activating receptors such as DNAM-1 belonging to the nectin family and 2B4 belonging to the SLAM family have been also described. 4 NK cell inhibitory receptors prevent auto-reactivity while allowing recognition and killing of stressed target cells.…”

Section: Introductionmentioning

confidence: 99%

The yin‐yang of the interaction between myelomonocytic cells and NK cells

et al. 2018

Self Cite

View full text Add to dashboard Cite

NK cells are innate lymphoid cells, which play a key role in the immune response to cancer and pathogens and participate in the shaping of adaptive immunity. NK cells engage in a complex bidirectional interaction with myelomonocytic cells. In particular, macrophages, dendritic cells and neutrophils promote differentiation and effector function of NK cells and, on the other hand, myelomonocytic cells express triggers of checkpoint blockade (eg PD-L1) and other immunosuppressive molecules, which negatively regulate NK cell function. In addition, NK cells express high levels of IL-1R8, which acts as a checkpoint for IL-18 driven differentiation and activation of NK cells. Evidence suggests that targeting the myeloid cell-NK cell crosstalk unleashes effective anti-tumour and anti-viral resistance.

show abstract

Nidogen-1 is a novel extracellular ligand for the NKp44 activating receptor

Cited by 59 publications

References 76 publications

Mechanisms of Resistance to NK Cell Immunotherapy

Mechanisms of Resistance to NK Cell Immunotherapy

Natural killer cells: From surface receptors to the cure of high‐risk leukemia (Ceppellini Lecture)

The yin‐yang of the interaction between myelomonocytic cells and NK cells

Contact Info

Product

Resources

About